Dow Up0.51% Nasdaq Up0.24%

Alnylam Pharmaceuticals, Inc. (ALNY)

-NasdaqGS
91.72 1.98(2.21%) Nov 21, 4:00PM EST
|After Hours : 91.72 0.00 (0.00%) Nov 21, 5:00PM EST
Income StatementGet Income Statement for:
View: Annual Data | Quarterly DataAll numbers in thousands
Period EndingDec 31, 2013Dec 31, 2012Dec 31, 2011
Total Revenue 47,167   66,725   82,757  
Cost of Revenue -   -   -  
Gross Profit 47,167   66,725   82,757  
Operating Expenses
Research Development112,957  86,569  99,295  
Selling General and Administrative27,152  44,612  38,280  
Non Recurring -  65,000   -  
Others -   -   -  
Total Operating Expenses -   -   -  
Operating Income or Loss (92,942) (129,456) (54,818)
Income from Continuing Operations
Total Other Income/Expenses Net1,022  17,392  674  
Earnings Before Interest And Taxes(91,920)(116,586)(57,649)
Interest Expense -   -   -  
Income Before Tax(91,920)(116,586)(57,649)
Income Tax Expense(2,695)(10,572) -  
Minority Interest -   -   -  
Net Income From Continuing Ops(89,225)(110,536)(61,154)
Non-recurring Events
Discontinued Operations -   -   -  
Extraordinary Items -   -   -  
Effect Of Accounting Changes -   -   -  
Other Items -   -   -  
Net Income (89,225) (106,014) (57,649)
Preferred Stock And Other Adjustments -   -   -  
Net Income Applicable To Common Shares (89,225) (106,014) (57,649)

Sign Up for a Free Trial to EDGAR Online Premium!
Get the critical business and financial information you need for more than 15,000 U.S. public companies.
Sign Up Now - Learn More

Currency in USD.